Variation between drug batches in developing countries poses “serious clinical implications” and should be tackled by regulators.
Elan has entered into a development and manufacturing agreement with German pharmaceutical company, Boehringer Ingelheim, for antibody-based therapeutics.
Albany Molecular Research Inc. (AMRI) has posted a fourth quarter loss for 2010 after charges relating to a non-cash goodwill and fixed asset impairment of $35.2m.
in-PharmaTechnologist presents a replay of our live blog covering all the news, views and multimedia from Informex 2011.
Novasep and instrAction have partnered to develop improved methods for the production of taxane-based active pharmaceutical ingredients (API) citing growing demand for cancer treatments as key driver.
The United States Pharmacopeoia (USP) will help regulators in sub-Saharan Africa ensure drug quality in a new scheme designed to boost testing and analysis capacity.
Outsourcing-pharma.com presents are round up of the latest expansion in the contracting sector with news from Helix Medical, Carbogen Amicus and A5 Labs.
A contract printing firm based in Winsford, UK has successfully achieved pharmaceutical industry accreditation.
CRO Particle Sciences (PSI) has formed a strategic partnership with Horiba to use its characterisation tools and service its clients.
The EMA has revised its EudraGMP database to give the public more information on GMP inspections.
Outsourcing-pharma.com rounds up the latest manufacturing contracts with news from SCM Pharma, Dalton Pharma Services and AMRI
US Heparin maker Scientific Protein Laboratories (SPL) says it has resolved “many of the issues” addressed in the US Food and Drug Administration (FDA) warning letter it received late last month.
Sigma-Aldrich has acquired analytical standards and certified reference materials manufacturer Resource Technology Corporation (RTC) to expand its analytical
Big pharma has taken a less heavy handed approach to relationships as cutbacks have made outsourcing key, according to Stephen Munk, CEO of Ash Stevens.
RecipharmCobra Biologics has received an EU patent for a genetic modification tech that allows antibiotic resistance genes to be removed after insertion is complete.